References
- Rehfeld JF , GingrasMH, BardramL, HilstedL, GoetzeJP, PoitrasP. The Zollinger–Ellison syndrome and mismeasurement of gastrin. Gastroenterology140, 1444–1453 (2011).
- Rifai N , WatsonID, MillerWG. Commercial immunoassays in biomarkers studies: researchers beware!Clin. Chem.58, 1387–1388 (2012).
- Gutiérrez OM , SunCC, ChenW, BabittJL, LinHY. Statement of concern about a commercial assay used to measure soluble hemojuvelin in humans. Am. J. Nephrol.36, 332–333 (2012).
- Prassas I , BrincD, FarkonaSet al. False biomarker discovery due to reactivity of a commercial ELISA for CUZD1 with cancer antigen CA125. Clin. Chem.60, 381–388 (2014).
- Rehfeld JF , BardramL, HilstedL, PoitrasP, GoetzeJP. Pitfalls in diagnostic gastrin measurements. Clin. Chem.58, 831–836 (2012).
- Git A . A recipe for disaster. Nature484, 439–440 (2012).
- Rehfeld JF . The art of measuring gastrin in plasma: a dwindling diagnostic discipline?Scand. J. Clin. Lab. Invest.68, 353–361 (2008).
- Servick K . Biomedicine. Woes for ‘exercise hormone’. Science20, 1299 (2015).
- ALbercht E , NorheimF, ThiedeBet al. Irisin – a myth rather than an exercise-inducible myokine. Sci. Rep.5, 1–10 (2015).
- Boström P , WuJ, JedrychowskiMP, KordeAet al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature481, 463–468 (2012).